HPV, China and Merck
Merck's HPV Vaccine Gains Approval in China for Men
Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending preventive healthcare to a broader demographic in China.
24/7 Wall St. on MSN5h
Merck Just Paid Investors: How Much Did They Receive?Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...
Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...
This was the stock's second consecutive day of gains.
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...
Zacks.com on MSN1d
Merck (MRK) Rises Higher Than Market: Key FactsMerck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback